Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.42 |
| ▸ | CBFB | Q13951 | 5/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7970550 | 0.93 | F9 (0.46) | NPBWR1NT5EGSK3BSLC2A1F9 | |
| SCHEMBL10172732 | 0.92 | MAP2K4 (0.38) | NPBWR1CBFBF9F10F11 | |
| SCHEMBL7971481 | 0.91 | HIF1A (0.46) | NPBWR1NT5EPTGDR2CHEK2 | |
| SCHEMBL7969075 | 0.91 | PTGDR2 (0.44) | NPBWR1NT5EGSK3BSLC2A1F9 | |
| SCHEMBL10139913 | 0.90 | F9 (0.43) | NPBWR1NT5EGSK3BF9F10 | |
| SCHEMBL7959240 | 0.90 | NPC1 (0.44) | NPBWR1NT5EGSK3BSLC2A1F9 | |
| SCHEMBL7969264 | 0.87 | MPL (0.46) | NPBWR1NT5EGSK3BPTGDR2CHEK2 | |
| SCHEMBL10139923 | 0.87 | CBFB (0.50) | CBFBGSK3BF9F10F11 | |
| SCHEMBL7970846 | 0.87 | CHEK2 (0.44) | NPBWR1NT5EGSK3BSLC2A1PTGDR2 | |
| SCHEMBL16258935 | 0.86 | CBFB (0.43) | NPBWR1CBFBNT5EGSK3BF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | NPBWR1 3598/4885CBFB 627/4885NT5E 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.